BASi, MicGenix Form Preclinical Pact

Bioanalytical Systems, Inc. (BASi) and MicaGenix, Inc. have entered a contract research partnership for complementary preclinical research services for pharmaceutical, medical device and biotechnology companies, as well as for medical schools. MicaGenix focuses on mutagenicity work, histopathology services, and regulatory package preparation and review; BASi is a pharmaceutical development company providing contract research services generally downstream from MicaGenix in pharmacokinetics, pharmacodynamics, in vivo toxicology and clinical trials.

Peter Kissinger, BASi chairman and chief executive officer, said, “For several years we have had common clients between several BASi laboratory sites and MicaGenix. There is very little overlap between our skill sets, and yet we have a number of opportunities to collaborate to the benefit of clients. MicaGenix leadership and technical staff benefit from many years of experience in association with Eli Lilly. This can now be put to work for the larger number of small discovery biology companies.”

MicaGenix president Joe Parton said, “The team at BASi has been in business longer than we have and it has been mutually beneficial to work with them as part of the Pharmaceutical Industry Contract Research Alliance (PICRA). We are delighted to formalize an even closer relationship whereby we each can market the services of the other and attract more business to Indiana. BASi has laboratory facilities in West Lafayette and Evansville, and an office in Indianapolis that we can share. MicaGenix is in Greenfield with close access to all three of those locations.”